Favourites   Have ideas?  Sign in / Register



Hematologic and musculoskeletal disorders segment

KROS Keros Therapeutics, Inc. - common stock -5.89% up -12.04% 6.15 + Biopharma, Medicine, Hematologic and musculoskeletal disorders

Last highlighted: #KROS SEC report: Keros Therapeutics, Inc. Quarterly report [Sections 13 or 15(d)]
SEC Filing Form 10-Q filed by Keros Therapeutics, Inc. -- SEC File Number 211148197
+ My List

We do not provide financial advice. All displayed data is the result of experiments, and a subjective assessment. All decisions that will be made based on this data are made at your own risk. Thank you for understanding.